

Regeneron
Generated by Meeveem AI
"Biotechnology research, medicine development, manufacturing and commercialisation"
About Regeneron
Regeneron invents, develops and commercialises medicines for serious diseases. Founded and led by physician-scientists, it uses technologies including VelociSuite and the Regeneron Genetics Center to turn research into treatments. Its portfolio spans eye disease, allergic and inflammatory conditions, cancer, cardiovascular disease and rare diseases. The company now lists 16 approved or authorised medicines and nearly 50 clinical candidates.
Founded in 1988 and headquartered in Tarrytown, New York, Regeneron has offices in 12 countries, including a UK office in Uxbridge, and clinical trials in more than 50 countries. It reported 15,410 full-time employees worldwide at the end of 2025, across research, clinical development, manufacturing and commercial operations.

Development across the business
Regeneron offers professional development courses and support for continuing education. Its teams cover the full medicine lifecycle, from discovery and regulatory work to product supply and commercial functions. In 2025, existing employees filled approximately a quarter of its job openings.

15410
Team Members
1988
Founded
Biotechnology
Sector
On-Site
Work Environment
Open Positions
Join our team! Explore current opportunities at Regeneron.
National Sales Manager Oncology Lung UK
Associate Director, Global Patient Safety - Ophthalmology
Manager, Global Patient Safety Scientist
Associate Director Medical Affairs UK (Oncology)
Associate Director Global Patient Safety
Associate Manager Regulatory Affairs
Manager, Medical Affairs Operations
Associate Director, Global Patient Safety Standards & Training
Senior Manager, Global Patient Safety
Director, Global Patient Safety Sciences Delivery - Rare Disease
Senior Manager GD GCP Auditing (UK)
Senior Manager, Statistical Programming